

REMARKS

This document is filed in reply to the office action dated July 22, 2004 ("Office Action"). Applicants have amended claims 2-6 to promote clarity and to correct informalities. No new matter has been introduced.

Claims 1-16 are pending and under examination. Reconsideration of this application is requested in view of the following remarks:

Objection to the Specification

The Examiner objected to the Specification, contending that "[t]he specification contains sequence disclosures that are not identified by SEQ ID NO[s] (e.g., page 14, lines 24-25 and page 15, lines 16-17)." See the Office Action, page 3, second paragraph.

Applicants disagree. The two passages of the Specification at issue disclose four PCR primers, i.e., (i) aagctcatga ttggcagcca gtctcgggc; (ii) gacctcatga accgtcgcta gcgacacgcc; (iii) ttaacgatcg ttagaagcaa acttaagagt g; and (iv) ttaacgatcg atgtaatcac tccttct. They, as well as other sequences disclosed in the Specification, are identified by SEQ ID NOs. See the sequence listing submitted with Applicants' response mailed April 22, 2002. For this reason, Applicants request that the objection be withdrawn.

Objection to claims 2 and 4-6

The Examiner objected to claims 2 and 4-6 for containing informalities. Applicants have corrected the informalities, and submit that the objection has been overcome.

Rejection under 35 U.S.C. § 112, second paragraph

The Examiner rejected claim 3 as being indefinite. See the Office Action, page 5, last paragraph. Applicants have amended this claim in the manner suggested by the Examiner, thereby overcoming the rejection.

Rejection under 35 U.S.C. § 112, first paragraph

The Examiner rejected claim 13, 15, and 16 under § 112, first paragraph on two grounds. Applicants traverse each below:

I

Claim 13, drawn to a DNA immunogenic composition, was rejected for lack of enablement. More specifically, it is the Examiner's position that he "can find no asserted use for an immunogenic composition according to the claims other than as a vaccine ... the disclosure fails to provide enablement for the broad scope of immunogenic composition comprising an antigenic gene, wherein said immunogenic compositions are useful as vaccines" See the Office Action, page 3, first paragraph.

Applicants disagree. Indeed, the Specification clearly teaches a number of uses of the claimed composition. For example, the composition, which contains a Lac shuttle vector, allows one "to express a heterologous gene in an organism or as a DNA vaccine or health food." See, e.g., the Specification, page 2, lines 11-15; and page 24, lines 15-18. In other words, the claimed composition has utilities other than vaccination. Further, the Specification provides sufficient teachings as to how to make and use the claimed composition. Thus, claim 13 meets the enablement requirement.

II

Claims 15 and 16, covering a Lac shuttle vector and a composition containing the vector, were rejected for containing new matter. The vector includes a nucleic acid encoding "a protein consisting essentially of the sequence of the Rep A protein." According to the Examiner, "the originally filed application and claims do not disclose a sequence for the Rep A protein." See the Office Action, page 5, second paragraph.

Applicants disagree and note that the Specification teaches such a sequence, e.g., a "Rep A protein ... of 317 amino acids." See, e.g., page 7, lines 21-28 of the Specification. In addition, as acknowledged by the Examiner, the just-quoted passage cites several references (e.g., Bouia et al, 1989, Plasmid, 22: 185-192), which disclose nucleic acids encoding the Rep A protein. See, the Office Action, page 2, lines 18-20.

In particular, Bouia et al., as well as the corresponding GenBank record, discloses the above-mentioned 317-amino acid Rep A protein and the encoding nucleotide sequence. See GenBank M31223 (copy attached hereto as "Exhibit A."). As shown in this exhibit, nucleotide (nt) 262-1215 of GenBank M31223 encodes the Rep A protein. In this connection, Applicants would point out that the Specification discloses the same nucleotide sequence, i.e., nt 3198-4151 of SEQ ID NO: 1 (i.e., FIGs. 5A-G) as originally filed. For the reasons set forth above, the Examiner clearly erred in asserting that "the originally filed application and claims do not disclose a sequence for the Rep A protein." To promote clarity, Applicants have amended the Specification to identify the amino acid sequence (SEQ ID NO: 8) and the nucleotide sequence (SEQ ID NO: 7) of the Rep A protein and submitted a copy of a substitute sequence listing.

CONCLUSION

Applicants submit that the rejections asserted by the Examiner have been overcome, and that the claims, as amended, define subject matter that is definite and sufficiently described. Allowance of this application is therefore proper, and early favorable action is solicited.


Please apply any other charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: 9-22-04

Y. Rocky Tsao
Y. Rocky Tsao
Attorney for Applicant
Reg. No. 34,053

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Books

Search for

Limits

Preview/Index

History

Clipboard

Details

Show: ☐ 1: M31223. Plasmid pLP1 (fro...[gi:149684]

Links

LOCUS LP1PLPREP 2093 bp DNA linear BCT 24-APR-1996
DEFINITION Plasmid pLP1 (from Lactobacillus plantarum CCM 1904) replication
protein (rep) gene, complete cds.
ACCESSION M31223
VERSION M31223.1 GI:149684
KEYWORDS replication protein.
SOURCE Plasmid pLP1
ORGANISM Plasmid pLP1
plasmids.
REFERENCE 1 (bases 1 to 2093)
AUTHORS Bouia, A., Bringel, F., Frey, L., Kammerer, B., Belarbi, A.,
Guyonvarch, A. and Hubert, J. C.
TITLE Structural organization of pLP1, a cryptic plasmid from
Lactobacillus plantarum CCM 1904
JOURNAL Plasmid 22 (3), 185-192 (1989)
MEDLINE 90222315
PUBMED 2517345
COMMENT Original source text: Plasmid pLP1 (tissue library: CCM 1904) DNA.
Draft entry and computer-readable sequence for [1] kindly submitted
by B. Kammerer, 11-JAN-1990.

FEATURES Location/Qualifiers
source 1..2093
/organism="Plasmid pLP1"
/mol_type="genomic DNA"
/specific_host="Lactobacillus plantarum"
/db_xref="taxon:2593"
/tissue_lib="CCM 1904"
/plasmid="Plasmid pLP1"
gene 249..1215
/gene="rep"
RBS 249..253
/gene="rep"
CDS 262..1215
/gene="rep"
/codon_start=1
/transl_table=11
/product="replication protein"
/protein_id="AAA98164.1"
/db_xref="GI:149685"
/translation="MSEIFEDKTENGKVRPWRERKIENVRYAEYLAILEFKRAHDVRG
CGEVLRFKIGEHLKLYQTWFKHRLCPLCNWRRSMKNSSQLKQIIAEAVAREPKGRF
LFLTLTVKNAHSAEELKVSLRALTKAFNKLTRYKKVTKNLLGYLRSTEITVNEQDGSY
NQHLHVLLFVKSSYFKNSNNYLAQAEWAKLWQKALKVDYEPVVHVQAVKANKRKGTD
LQASAEETAKYEVKSADYMTADDERNLVVIKNLEYALAGTRQISYGGLLKQIKQDLKL
EDVENGDLVHVGDEDYTKEQMEAAEEVVAKWDFNKQNYFIW"
repeat_region 1335..1351
/note="direct repeat A"
repeat_region 1352..1368
/note="direct repeat B"
repeat_region 1369..1385
/note="direct repeat C"
repeat_region 1386..1402
/note="direct repeat D"
repeat_region 1403..1419

repeat_region /note="direct repeat E"
1420..1436
repeat_region /note="direct repeat F"
1437..1453
repeat_region /note="direct repeat G"
1456..1467
repeat_region /note="direct repeat H"
1468..1484
repeat_region /note="direct repeat I"
1485..1501
repeat_region /note="direct repeat J"
1504..1520
repeat_region /note="direct repeat K"
1521..1537
repeat_region /note="direct repeat L"
1538..1554
repeat_region /note="direct repeat M"
2051..2064
rep_origin /note="origin of replication (put.); putative"

ORIGIN 1 bp upstream of HindIII site.

1 aagcttgatt aggcttaatt gggcttgat ccatgtatt tataggcttt tgggtatta
61 ttaggggtat aaattggtg aaagaaagac aaaataaaaa cccacgtgca aattcctagt
121 ttggccgctc ggaacacgtg agttgattat catttgcgat ttatagccta ttctagggga
181 aaagccctat gatgtcaagg ttataagctt attgaaaaag atagtcagct ccttcacgtg
241 gataaactgg aggagctttt tatgtcagaa atttttgaag ataaaaactga aaatggcaaa
301 gttagacctt ggcgagaacg gaagattgaa aatgtgcgt atgccgaata ttiggcaatc
361 ttagaattta aacgggcaca tgatgtacgg ggttgtggtg aagttttgctg ttttcgtaag
421 attggcgaag acttaaaact ttatcaaacg tggttttgtc ataaacgatt gtgtccattg
481 tgtaattgga gaaggagcat gaaaaactcg agccagttaa aacaaattat tgcggaagca
541 gttgcaagag agcctaaagg acggtttttg tttttaactt taaccgttaa aaacgctcat
601 tcagcagagg agttaaaggt gtctttaaga gcttgacta aagcctttaa taagctaact
661 cgctataaaa aagtactaa aaatttattg ggttatttac gttcaacgga aattaccgtt
721 aatgaacaag acgggtcata taatcaacac ttgcatgtgt tgctgtttgt aaaaatcaagt
781 tattttaaga attcaataaa ttatttagca caagcagaat gggcaaaatt atggcaaaaa
841 gccttgaaag ttgattatga gcctgtggtg catgtgcagg ctgttaaagc taacaaacgt
901 aaaggaactg actctttgca agctagtgc gaagaaacgg cgaaatacga ggtaaaatca
961 gctgattata tgacggctga tgatgagcgt aatttggtg tgattaaaaa ttggagtat
1021 gccttagctg gaacacgaca aatcagctat ggtggattat taaagcaaat taagcaagat
1081 ttgaaacttg aagatgttga gaatggtgat ttagttcatg ttggcgatga agattacacc
1141 aaagagcaaa tggaaactgc ggaagaagtt gtgcgaaaat gggattttta taaacaaaaat
1201 tattttattt ggtaagaga atgtcaggat atgatcaacg gtaaatccgt tggcatatcc
1261 cttttttgtt gtcagcttgc tgacttctga tacaggtttt agcattactc caatttattt
1321 ggagtgtgaa tgcacattat catgtagtgc gcattatcat gtagtgcgca ttatcatgta
1381 gtgcgcatta tcatgtagt cgcattatca ttagtgcgca attatcatgt agtgcgcatt
1441 atcatgtagt gcgcacatta tcatgtacat tatcatgtag tgcgcattat catgtagtgc
1501 gcacattatc atgtagtgcg cattatcatg tagtgccgat tatcatgtag tgcgcactta
1561 cacacaacat gaagttgtgt tgtgctaaac ccatcaaaac ctgcatcaga tttcgcgttg
1621 ctcaaacgta actgacttgc gtcagtttgg aacattcaaa aataaataag ttcagtcgct
1681 agtccttctg aactttttta tttttgaacg ttaattttta aggcctctat ttgcgttcta
1741 agcgatttta gctaacagtt agctatctaa ctgtctgtca acggtaaatc gacttagagg
1801 ggcttattga gccttacagg cgatattagc cctcttggga ggctttaagg agttgataga
1861 ctagacaata ccaaaagcct gacgtcttgg aaaacaagcc cttgttttcc cgagcccagc
1921 ggcggaagc gttacggctc agctggttca gctggtcagt gtggctgaaa gccacggttt
1981 aaaaaaagca gttcagcggg ttttgcgtat ctgctttttg ggggttaaaa acgcaatttt
2041 tggcgttttc ttcttatctt gatactatta gcaacaacta gttttttaaa atc

nt 262-1215

//

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Aug 30 2004 07:13:44